Exploring new frontiers for the pharmacological treatment of insomnia
Insomnia is the most common sleep disorder and approximately 10% of the world’s population will report that they suffer from chronic or persistent insomnia [1]. Insomnia is a condition of unsatisfactory sleep, either in terms of sleep onset, sleep maintenance or early waking. Furthermore, insomnia i...
| Autores: | , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2014 |
| País: | España |
| Institución: | Universidad Camilo José Cela (UCJC) |
| Repositorio: | Depósito Digital e-UCJC |
| OAI Identifier: | oai:repositorio.ucjc.edu:20.500.12020/769 |
| Acceso en línea: | http://hdl.handle.net/20.500.12020/769 |
| Access Level: | acceso abierto |
| Palabra clave: | Psicología Pharmacological Treatment Insomnia 3201.05 Psicología Clínica 3209 Farmacología |
| Sumario: | Insomnia is the most common sleep disorder and approximately 10% of the world’s population will report that they suffer from chronic or persistent insomnia [1]. Insomnia is a condition of unsatisfactory sleep, either in terms of sleep onset, sleep maintenance or early waking. Furthermore, insomnia impairs daytime well-being and subjective abilities and functioning. Insomnia must be considered a ‘24-hour’ disorder [2]. In contrast with DSM-IV, the new Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-V) does not distinguish between primary insomnia and secondary insomnia. DSM-V recognizes that co-existing medical or mental conditions with sleep disorders (comorbid insomnia) are interactive and bidirectional. For this reason, the diagnosis of primary insomnia has been renamed insomnia disorder [3]. This change in the definition of insomnia will most likely change the approach to insomnia drug development. |
|---|